APA (7th ed.) Citation

Makaro, A., Świerczyński, M., Pokora, K., Sarniak, B., Kordek, R., Fichna, J., & Salaga, M. (2024). Empagliflozin attenuates intestinal inflammation through suppression of nitric oxide synthesis and myeloperoxidase activity in in vitro and in vivo models of colitis. Inflammopharmacology, 32(1), 377. https://doi.org/10.1007/s10787-023-01227-8

Chicago Style (17th ed.) Citation

Makaro, Adam, Mikołaj Świerczyński, Kacper Pokora, Barbara Sarniak, Radzisław Kordek, Jakub Fichna, and Maciej Salaga. "Empagliflozin Attenuates Intestinal Inflammation Through Suppression of Nitric Oxide Synthesis and Myeloperoxidase Activity in in Vitro and in Vivo Models of Colitis." Inflammopharmacology 32, no. 1 (2024): 377. https://doi.org/10.1007/s10787-023-01227-8.

MLA (9th ed.) Citation

Makaro, Adam, et al. "Empagliflozin Attenuates Intestinal Inflammation Through Suppression of Nitric Oxide Synthesis and Myeloperoxidase Activity in in Vitro and in Vivo Models of Colitis." Inflammopharmacology, vol. 32, no. 1, 2024, p. 377, https://doi.org/10.1007/s10787-023-01227-8.